伊贝沙坦联合倍他乐克治疗慢性充血性心力衰竭临床观察.doc

伊贝沙坦联合倍他乐克治疗慢性充血性心力衰竭临床观察【摘要】目的：观察伊贝沙坦联合倍他乐克治疗慢性充血性心力衰竭(CHF)的临床疗效。方法：62例CHF患者随机分为两组。对照组30例常规行洋地黄、利尿剂及血管扩张剂治疗。治疗组32例在常规治疗的基础上加用伊贝沙坦及倍他乐克治疗，治疗4~6周，观察治疗前后心率、血压、心胸比、左室舒张末期内经、左室射血分数以及心功能的变化。结果：治疗组经治疗后心率、血压心胸比、左室内经，与治疗前比较差异有显著性(P0.05、P0.01)，左室射血分数增加(P0.01)，心功能改善1~2级。药物不良反应少，患者耐受性好。结论：在常规治疗的基础上加用伊贝沙坦及倍他乐克治疗CHF有效。 【关键词】伊贝沙坦；倍他乐克；慢性充血性心力衰竭 文章编号：1009-5519（2007）15-2232-03 中图分类号：R5 文献标识码：A Observation on the clinical effect of irbesartan combined with betaloc in congestive heart failure YIN An-kang (The Fourth People’s Hospital of yangzhou,Jiangsu 225002,China) 【Abstract】Objective:To observe the clinical effect of irbesartan combined with betaloc in the treatment of congestive heart failure.Methods:62 patients with congestive heart failure were randomly divided into the treatment group(32 cases) and control group(30 cases).The control group was administrated routinely with digitalis,diuretic and vasodilator agent,besides those,the treatment group was added with irbesartan and betaloc for 4 to 6 weeks.The changes of heart rate(HR),blood pressure(BP),cardiothoracic ratio,left ventricular end diastolic diameter(LVDD),left ventricular ejection fraction(LVEF) and cardiac function(NYHA) were observed respectively.Results:In the treatment group after 4 to 6 weeks,HR,BP,cardiothoracic ratio and LVEDD all decreased significantly (P0.05,P0.01),LVEF increased(P0.01) and cardiac function (NYHA) improved grads 1~2 compared with those before treatment.Irbesartan and betaloc had few adverse effects and the patient’s tolerance was perfect.Conclusion:It is effective to treat congestive heart failure with irbesartan and betaloc on the basis of routine treatment. 【Key words】Irbesartan；Betaloc；Chronic congestive heart failure 我院2002年3月～2006年10月收治的62例慢性充血性心力衰竭（CHF）患者，在常规治疗的基础上加用伊贝沙坦及倍他乐克，观察其疗效，总结如下。 1 资料与方法 1.1 一般资料：62例CHF患者心功能分级Ⅱ～Ⅳ级，其中风湿性心瓣膜病合并CHF 7例，冠心病合并CHF 32例（其中陈旧性下壁心肌梗死12例，陈旧性前壁心肌梗死10例，陈旧性高侧壁心肌梗死10例），扩张型心肌病合并CHF 5例，高血压性心脏病合并CHF 18例。随机分为两组：治疗组32例，男20例，女12例，年龄52~76